

Users of prescription drugs (NHC) – users per 1000 inhabitants, age standardised

Year				2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	
Geography	Drug group	Age	Gender																		
Nordland	Total all drug groups	0-44 yrs	both genders	572	584	579	587	600	586	591	584	573	577	575	576	579	582	594	574	590	
			men	490	503	498	510	529	509	513	508	491	494	492	492	498	498	512	488	506	
			women	657	669	664	670	675	669	673	666	662	666	666	664	666	669	674	683	668	682
		45-74 yrs	both genders	792	803	807	812	817	814	817	821	817	818	820	819	821	821	822	815	826	
			men	737	752	757	767	775	771	775	778	774	773	775	778	777	776	778	772	782	
			women	850	857	860	859	861	860	862	865	863	865	868	863	867	867	867	867	860	871
	Insulins and analogues (A10A)	0-44 yrs	both genders	5	5	6	6	6	6	6	6	6	6	6	6	6	6	6	6	6	7
			men	6	6	6	6	7	7	7	7	7	7	7	7	7	7	7	7	7	8
			women	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5
		45-74 yrs	both genders	17	17	18	18	18	19	19	19	19	19	19	19	20	20	20	21	21	21
			men	20	20	21	22	22	22	23	22	22	23	23	24	25	25	26	25	26	
			women	14	14	14	14	15	16	15	15	16	15	15	15	16	15	15	16	16	
	Cardiovascular disease, treatment/prevention, except lipid modifying agents (C except C10)	0-44 yrs	both genders	27	28	29	30	31	32	33	34	36	36	36	36	34	35	35	35	37	
			men	24	25	26	27	27	29	30	31	32	33	31	32	31	31	32	30	32	
			women	31	31	32	34	34	35	36	37	40	40	41	41	38	39	40	40	42	
		45-74 yrs	both genders	314	321	327	332	335	337	337	336	335	334	329	329	325	322	318	315	318	
			men	320	325	332	341	345	351	352	351	351	351	348	349	348	344	342	340	342	
			women	308	316	321	323	325	322	320	320	317	315	310	308	300	299	293	290	293	
	Lipid modifying agents (C10)	0-44 yrs	both genders	6	7	8	8	8	9	8	8	7	7	7	7	7	7	6	6	7	
			men	8	9	10	11	10	11	11	10	10	9	9	9	9	9	8	8	9	
			women	5	5	6	6	6	6	5	5	5	4	4	4	5	4	5	5	5	
45-74 yrs		both genders	169	180	195	204	210	215	215	211	205	199	196	193	193	191	186	185	192		
		men	184	196	210	219	227	233	237	233	228	225	224	223	224	222	220	221	228		
		women	153	164	179	187	192	195	193	187	180	173	166	161	161	158	151	149	154		
Antiinflammatory and antirheumatic products, non-steroids (M01A)	0-44 yrs	both genders	125	128	133	130	124	124	120	117	117	113	111	112	113	111	113	109	114		
		men	114	115	119	118	113	113	107	104	104	98	97	95	95	92	96	89	94		

		women	137	143	147	143	136	136	134	131	131	128	126	130	133	131	132	131	136	
	45-74 yrs	both genders	260	268	269	265	257	262	255	254	252	246	250	244	244	239	238	243	249	
		men	222	229	231	232	228	234	227	225	226	220	220	215	215	210	208	213	219	
		women	300	308	308	300	288	291	284	283	278	274	281	275	275	269	270	274	281	
Painkillers, Opioids (N02A)	0-44 yrs	both genders	56	57	59	60	59	59	58	60	60	59	62	63	63	61	60	57	59	
		men	53	53	54	54	54	53	52	55	54	53	54	54	53	52	51	48	50	
		women	60	61	65	66	64	65	64	65	66	66	66	70	73	73	72	69	66	69
	45-74 yrs	both genders	136	137	139	144	138	139	136	142	142	146	150	151	149	146	144	141	143	
		men	122	124	122	130	126	126	124	130	131	134	136	138	135	134	130	130	128	
		women	152	151	156	159	150	152	149	154	155	159	164	165	163	159	157	152	157	
Painkillers, other (N02B)	0-44 yrs	both genders	16	18	25	28	29	31	35	36	37	38	41	44	49	53	57	60	65	
		men	13	15	21	23	25	25	27	29	28	28	31	33	36	38	41	44	47	
		women	19	21	28	33	34	37	42	44	45	49	51	56	62	69	74	79	85	
	45-74 yrs	both genders	51	57	68	78	83	92	102	110	114	123	130	138	150	161	176	188	198	
		men	39	43	51	60	64	73	80	85	87	94	99	106	115	125	137	146	154	
		women	64	71	85	97	103	111	124	135	141	153	162	171	187	199	217	233	243	
Drugs for mental disorders, incl. hypnotics (N05A, N05C, N05B, N06A)	0-44 yrs	both genders	39	39	41	41	41	42	42	44	45	45	46	47	47	49	52	55	57	
		men	31	32	33	33	33	34	34	35	36	36	36	37	36	37	38	40	41	
		women	46	47	49	49	49	51	51	53	54	55	57	58	60	63	67	72	75	
	45-74 yrs	both genders	99	101	103	101	100	100	101	101	101	102	103	103	102	103	105	108	111	
		men	70	70	71	70	70	70	71	72	71	72	71	72	72	72	74	76	78	
		women	130	133	136	133	132	131	133	131	132	133	135	135	133	135	138	141	145	
Antipsychotics (N05A)	0-44 yrs	both genders	11	11	12	11	12	12	12	12	12	11	12	13	13	14	15	15	16	
		men	11	11	12	11	12	12	12	12	12	12	12	13	13	13	13	14	15	15
		women	11	11	12	11	11	12	12	11	12	11	12	13	13	14	15	16	17	
	45-74 yrs	both genders	31	30	29	28	28	26	26	26	25	25	25	25	25	25	25	26	26	27
		men	27	26	26	24	24	23	23	24	22	22	22	22	22	22	22	23	23	24
		women	34	34	33	32	31	29	30	29	28	28	28	28	28	28	28	29	28	29
Antidepressants (N06A)	0-44 yrs	both genders	32	32	34	34	35	35	36	37	38	38	39	40	40	41	44	46	48	
		men	25	25	25	27	26	26	27	28	29	28	28	29	28	28	30	31	31	
		women	40	41	43	43	43	44	45	47	48	49	51	52	53	55	59	63	66	

		45-74 yrs	both genders	80	82	85	84	84	84	86	85	86	88	88	88	87	88	90	93	95	
			men	51	53	54	53	54	55	57	56	57	58	58	59	58	58	59	61	63	
			women	110	113	117	115	114	115	117	116	116	118	121	120	118	119	123	125	128	
	Hypnotics, sedatives and anxiolytics (N05C, N05B)	0-44 yrs	both genders	41	43	45	47	47	47	50	49	48	50	50	51	53	56	58	59	60	
			men	34	35	37	39	41	40	42	43	42	43	43	43	43	46	47	50	51	52
			women	48	51	53	55	54	54	57	55	55	57	58	59	62	65	66	69	70	
		45-74 yrs	both genders	170	173	173	175	172	171	169	165	163	163	162	159	157	154	153	152	151	
			men	115	118	119	121	120	120	116	114	113	114	113	114	112	109	109	109	109	
			women	227	230	229	230	226	224	223	217	215	214	212	206	205	202	200	196	195	
	ADHD drugs (Attention Deficit Hyperactivity Disorder) (C02AC02 and N06BA except N06BA07)	0-44 yrs	both genders	7	8	9	12	13	15	15	15	16	16	17	18	18	19	20	21	24	
			men	10	11	13	15	17	18	18	18	19	19	20	21	21	22	23	25	27	
			women	4	5	6	8	10	11	11	12	13	13	14	15	15	15	16	18	20	
		45-74 yrs	both genders	0	0	1	1	1	1	1	2	2	2	3	3	4	4	5	6	7	
			men	0	1	1	1	1	1	1	2	2	2	3	4	4	4	5	6	7	
			women	0	0	1	1	1	1	1	2	2	2	3	3	4	4	5	5	6	
	Asthma and chronic obstructive pulmonary disease (COPD) drugs (R03 except R03CA)	0-44 yrs	both genders	60	61	60	61	65	68	68	68	65	65	64	65	65	66	67	64	68	
			men	61	61	60	61	65	69	68	68	64	64	63	65	64	65	64	61	64	
			women	59	61	60	61	64	66	67	68	65	66	66	66	66	68	70	68	72	
		45-74 yrs	both genders	87	87	88	87	89	90	92	94	94	96	100	102	107	108	111	110	109	
			men	72	71	73	72	75	74	77	77	78	80	83	87	92	95	97	95	94	
			women	103	103	104	101	104	108	108	111	111	113	117	118	122	123	127	126	125	
	Antihistamines (allergy medicines) (R06A, R01AC, R01AD, R01B, S01G)	0-44 yrs	both genders	125	128	128	131	131	127	133	132	128	137	132	137	147	147	159	162	170	
			men	113	114	115	118	121	114	119	117	113	123	116	121	128	128	138	142	147	
			women	137	142	141	144	142	141	147	147	143	153	148	153	166	169	181	184	195	
		45-74 yrs	both genders	135	138	144	145	146	147	152	156	156	163	164	166	175	179	188	193	199	
			men	96	99	103	103	106	109	110	115	115	122	121	123	131	133	140	144	148	
			women	175	180	186	188	188	188	195	200	200	205	209	211	221	227	237	243	250	
Troms og Finnmark	Total all drug groups	0-44 yrs	both genders	552	557	559	572	587	568	567	564	557	553	553	554	560	562	572	559	578	
			men	465	469	479	491	509	482	486	482	472	465	467	469	475	477	487	472	493	
			women	644	650	645	658	670	660	654	654	650	649	649	650	654	656	665	656	671	

	45-74 yrs	both genders	771	774	784	793	800	796	800	800	798	795	796	798	799	799	797	791	801	
men		723	725	739	748	756	754	757	757	755	752	751	754	755	755	756	746	755		
women		823	825	832	841	847	841	845	846	843	841	844	845	845	847	841	839	850		
Insulins and analogues (A10A)	0-44 yrs	both genders	5	5	5	5	5	5	5	5	5	6	6	5	6	6	6	6	7	
		men	5	5	5	6	6	6	6	6	6	6	6	6	6	6	6	7	7	
		women	4	4	4	5	5	5	5	5	5	5	5	5	5	5	5	6	6	6
	45-74 yrs	both genders	18	18	19	19	19	20	19	19	20	20	20	21	21	21	21	21	21	21
		men	20	21	21	22	23	23	23	23	24	24	24	25	25	25	26	26	26	
		women	15	15	15	15	16	16	15	15	16	16	16	16	16	17	17	16	17	
Cardiovascular disease, treatment/prevention, except lipid modifying agents (C except C10)	0-44 yrs	both genders	27	29	30	31	31	32	33	34	35	36	36	36	34	34	35	34	36	
		men	23	24	26	27	28	28	29	31	31	31	32	31	30	31	31	31	32	
		women	31	33	34	34	35	36	37	37	39	41	41	40	39	38	39	38	41	
	45-74 yrs	both genders	307	314	320	332	334	333	330	331	332	329	325	324	318	315	310	306	308	
		men	310	319	326	340	342	343	341	343	344	342	340	339	335	333	329	325	327	
		women	304	309	314	323	325	324	319	319	318	315	310	308	301	296	290	287	287	
Lipid modifying agents (C10)	0-44 yrs	both genders	5	5	6	7	7	8	7	7	7	6	6	6	6	6	6	6	6	
		men	7	7	9	9	10	10	10	9	9	8	8	8	8	8	8	7	8	
		women	3	3	4	4	5	5	5	4	4	4	4	4	4	4	4	4	4	
	45-74 yrs	both genders	160	172	183	196	205	213	215	212	207	203	199	196	195	194	189	186	191	
		men	178	190	201	214	223	232	234	232	230	228	225	222	224	224	222	221	226	
		women	141	151	164	176	186	193	195	191	184	177	172	169	164	161	154	151	155	
Antiinflammatory and antirheumatic products, non-steroids (M01A)	0-44 yrs	both genders	126	124	126	127	124	121	119	116	108	105	105	103	104	100	102	99	105	
		men	113	110	114	115	113	106	107	102	93	91	89	85	88	85	85	81	87	
		women	139	138	139	140	136	136	131	132	125	121	122	122	121	117	120	119	126	
	45-74 yrs	both genders	246	245	246	244	244	243	238	239	229	224	224	220	220	214	207	210	214	
		men	212	209	214	214	215	217	211	209	200	195	193	189	189	183	178	180	182	
		women	282	283	279	275	275	271	266	270	259	254	256	253	253	246	237	241	249	
Painkillers, Opioids (N02A)	0-44 yrs	both genders	59	59	63	63	64	64	64	66	66	65	63	64	64	63	62	61	61	
		men	54	55	57	58	59	58	58	58	58	55	53	54	55	54	53	53	52	
		women	64	64	69	69	69	71	71	74	74	75	75	74	74	73	71	69	70	

	45-74 yrs	both genders	137	140	146	147	148	149	152	151	153	156	156	156	155	151	148	147	151
men		123	125	133	134	133	137	140	138	138	144	143	141	141	137	134	134	139	
women		151	155	159	162	163	163	165	165	168	168	170	171	171	167	163	161	163	
Painkillers, other (N02B)	0-44 yrs	both genders	15	16	20	24	27	31	36	38	39	42	43	44	49	52	58	60	65
		men	12	13	17	20	23	25	30	30	29	31	32	33	38	40	43	44	49
		women	17	20	24	28	32	37	43	47	49	53	55	56	62	64	75	77	84
	45-74 yrs	both genders	42	48	56	66	76	88	101	108	114	123	129	136	148	161	171	185	194
		men	32	36	43	50	58	69	78	84	86	95	99	104	113	122	130	143	150
		women	52	61	70	83	94	108	124	132	143	154	161	170	184	201	215	230	240
Drugs for mental disorders, incl. hypnotics (N05A, N05C, N05B, N06A)	0-44 yrs	both genders	34	34	33	34	35	36	37	37	37	36	37	38	38	39	40	41	45
		men	27	27	26	27	28	29	29	29	29	28	29	29	30	29	30	31	33
		women	41	41	41	41	43	43	45	46	46	46	47	48	48	50	50	53	58
	45-74 yrs	both genders	84	84	83	83	83	83	83	82	83	83	84	84	84	85	86	86	88
		men	61	60	61	60	60	60	59	60	61	61	61	61	61	62	62	62	63
		women	108	108	107	107	107	108	108	106	107	107	108	109	108	109	110	111	114
Antipsychotics (N05A)	0-44 yrs	both genders	11	12	11	11	12	11	11	11	11	11	11	11	12	13	12	13	14
		men	11	11	10	11	12	11	11	11	11	11	11	11	11	12	12	12	13
		women	12	12	11	11	11	11	11	11	11	10	11	11	12	14	12	13	15
	45-74 yrs	both genders	32	32	30	29	29	29	28	28	27	27	26	26	26	26	26	27	26
		men	27	27	26	25	25	25	24	24	23	23	23	23	23	23	23	24	23
		women	36	37	35	34	33	33	32	32	31	30	30	29	29	30	30	30	30
Antidepressants (N06A)	0-44 yrs	both genders	26	26	27	27	28	29	30	30	30	29	30	31	31	31	32	34	36
		men	19	19	19	20	20	21	22	22	22	20	22	22	22	22	22	23	24
		women	33	34	34	35	36	36	38	40	40	39	40	41	41	42	43	45	50
	45-74 yrs	both genders	61	62	63	63	64	64	65	64	65	66	66	67	67	67	69	69	71
		men	40	40	42	42	43	43	43	44	44	45	45	45	45	46	47	46	48
		women	84	84	85	85	85	86	87	86	88	88	89	91	90	90	91	93	96
Hypnotics, sedatives and anxiolytics (N05C, N05B)	0-44 yrs	both genders	39	40	41	43	46	44	45	45	46	46	46	46	48	49	52	53	55
		men	31	32	34	36	39	38	38	39	39	39	38	39	41	41	44	44	46
		women	48	48	49	50	53	51	52	52	53	54	55	54	56	57	61	62	65

ADHD drugs (Attention Deficit Hyperactivity Disorder) (C02AC02 and N06BA except N06BA07)	45- 74 yrs	both genders	151	154	156	160	159	155	155	150	151	147	146	145	142	138	138	135	136
		men	103	108	109	110	111	110	110	106	108	104	104	103	100	100	99	97	99
		women	201	203	204	212	209	203	203	197	196	193	191	188	185	178	179	175	175
	0- 44 yrs	both genders	5	5	7	7	8	8	9	9	10	10	10	11	11	11	13	14	17
		men	7	8	9	9	10	11	11	12	12	13	13	13	13	14	15	17	20
		women	3	3	4	5	5	6	6	6	7	7	8	8	9	9	10	12	14
	45- 74 yrs	both genders	0	0	0	1	1	1	1	1	1	2	2	2	2	3	3	4	4
		men	0	0	0	1	1	1	1	1	1	2	2	2	3	3	3	4	4
		women	0	0	0	0	1	1	1	1	1	1	2	2	2	2	3	3	4
Asthma and chronic obstructive pulmonary disease (COPD) drugs (R03 except R03CA)	0- 44 yrs	both genders	60	61	62	65	65	67	68	69	67	67	67	68	69	69	70	69	74
		men	59	59	60	65	64	67	66	68	66	66	65	65	66	66	67	65	71
		women	61	62	64	66	65	68	70	70	69	68	69	72	72	71	73	73	78
	45- 74 yrs	both genders	95	95	95	97	100	101	103	106	108	108	112	114	118	120	121	121	121
		men	78	78	78	81	84	86	87	89	90	91	93	96	100	101	101	102	102
		women	113	113	112	113	116	118	120	125	126	127	131	133	137	141	142	142	140
Antihistamines (allergy medicines) (R06A, R01AC, R01AD, R01B, S01G)	0- 44 yrs	both genders	115	115	118	118	120	117	119	119	120	125	123	126	132	136	141	142	152
		men	100	101	105	106	107	103	104	101	104	108	105	108	111	115	120	121	131
		women	131	131	132	131	134	132	135	137	138	144	143	146	155	159	165	165	175
	45- 74 yrs	both genders	122	125	129	137	138	140	142	148	148	152	155	158	164	168	171	173	178
		men	86	87	90	98	99	100	102	106	105	109	110	113	117	121	123	123	129
		women	161	166	171	177	178	182	183	193	194	198	202	205	214	218	220	225	229

CellMark Legend

- .. Missing data
- . Not possible to calculate
- : Hidden value

Description

Users of prescription drugs among 0-79 year olds. Users are defined as people who have been dispensed at least one prescription in the reporting period.

Four measures are available. Use the Measures menu to select:

1. number of users (shown on national level only due to privacy protection)
2. users per 1000 = number of users per 1000 inhabitants of same sex and age per year
3. users per 1000 age standardized = number of users per 1000 inhabitants of same sex and age per year, age standardised. Age standardisation of rates reduces the effect of differing age distributions when groups are compared over time and between geographical regions.
4. Ratio (Norway=100): The ratio between the standardized rate in the county and the national rate for a given year. A ratio of 130 means that the county rate is 30 % higher than the national rate. A ratio of 87 means that the county rate is 13 % lower than the national level.

In the Norwegian Prescription Database, every individual is registered with a pseudonymous serial number which makes it possible to link drug consumption to individuals

without knowing who they are. Even if a person has dispensed a prescription for the same drug several times, they are only counted as a user once.

Drug consumption cannot be assumed to be synonymous with disease prevalence. The exception is the use of drugs to treat diabetes mellitus, which can be considered a good indicator for prevalence of diabetes. A lot of patients use multiple drugs, e.g. both anti-depressives and hypnotics, so will be included in both groups. It is therefore not possible to simply add the number of users in two groups of drugs to find out how many users there are in total.

Figures in Norhealth may vary slightly from the Norwegian Prescription Database because data may have been extracted from the main database at different times.

Drugs are classified according to the ATC system (see below).

The following groups of drugs are included *:

All drugs in total

Diabetes drugs (A10)

- Insulins and analogues (A10A)

Cardiovascular disease, treatment/prevention (C)

- Cardiovascular disease, treatment/prevention, except Lipid modifying agents (C except C10)

- Lipid modifying agents (C10)

Painkillers (analgetics) (M01A, N02A, N02B)

- Antiinflammatory and antirheumatic products, non-steroids (M01A)

- Painkillers, Opioids (N02A)

- Painkillers, other (N02B)

- Antimigraine preparations (N02C)

Drugs for mental disorders (N05A, N06A)

- Antipsychotics (N05A)

- Antidepressants (N06A)

Hypnotics and anxiolytics (N05B, N05C)

- Hypnotics (N05C)

- Hypnotics, addictive (N05C excl. N05CH01 and N05CD08)

ADHD drugs (Attention Deficit Hyperactivity Disorder) (C02AC02 and N06BA except N06BA07)

Asthma and chronic obstructive pulmonary disease (COPD) drugs (R03 except R03CA)

Antihistamines (allergy medicines) (R06A, R01AC, R01AD, R01B, S01G)

- Antihistamines for systemic use (R06A)

Prescriptions for antibiotics are presented in a separate, neighbouring table.

Data on Blood glucose lowering drugs, excluding insulins (A10B) are presented under Health and disease/ Disease groups/ Type 2 diabetes, indicators.

News, March 2019:

- New subgroup: Hypnotics, addictive - comprising all hypnotics except melatonin and midazolam.

- ADHD drugs now include guanfacin (C02AC02).

- Drugs against asthma and chronic obstructive pulmonary disease (COPD) now exclude R03CA. The former group "Asthma and COPD (R03)" has been discontinued.

Drugs are classified according to the ATC-system (Anatomic, Therapeutic, Chemical classification). By using this international classification system one can make statistics of drug consumption groups at 5 different levels, including from figures that show total use of all preparations classified under a main group (1st level, e.g. group C - Heart and circulation), figures for the different sub-groups (2nd, 3rd and 4th level) and down to figures that show use of each active ingredient.

Further information about the Norwegian Prescription Database can be found at www.norpd.no.

See also Drug Consumption in Norway at www.drugconsumption.no.

* Some of the drugs can be bought without a prescription, e.g. in small packages. Such use is not included in the statistics.

Rationale for indicator

For many diseases, we have insufficient data on prevalence. Drug use is not synonymous with disease prevalence, but can be an indicator for the prevalence of a disease.

Source

Norwegian Institute of Public Health, Department of Pharmacoepidemiology

Collection

The Norwegian Prescription Database contains information on all prescriptions dispensed from Norwegian pharmacies for both human and animal use. The register only contains information that directly or indirectly concerns prescriptions. Information about the patient and prescriber is pseudonymous.

Interpretation and sources of error

Purchases of over the counter drugs from a pharmacy or grocery store are not included. People over 80 years are excluded because there are varying proportions in each county who live at institutions where drugs are provided by the institution rather than via private prescriptions. Figures are also not presented for inappropriate combinations of age and drug groups, for example anti-dementia medicines for children.

Data quality

The data quality is very good.

Statistical analysis

Age standardization is done using direct standardization. The standard population is the sum of men and women in each age group in Norway per 1.January 2012.

When numbers are missing

Statistics based on fewer than five cases are hidden for privacy reasons. The same is done where the population segment from which the data are collected is less than ten.

If more than 20 per cent of the numbers in a time series are hidden for privacy reasons, the entire time series is concealed so as not to create a false impression of the situation in the county. Time series are also hidden where more than 50 per cent of the numbers in the time series are based on 6 or fewer cases.

Time periods

2005-2021

Geographical level

Country, health region, counties

Gender

Both genders, men, women

Age groups

0-74 years, 0-44 years (0-17, 18-24, 25-44), 45-74 years. Additionally, 0-79 years and 18-79 years.

Frequency of updates

Annually

Last updated

4/27/22

Keywords

Click on a keyword to search for similar indicators.

- Antibiotics
- Antihypertensives
- Antipsychotics

- Anxiety
- Asthma
- Betablockers
- Blood lipids
- Blood pressure
- Blood sugar
- Calcium antagonists
- Cholesterol
- Contraceptives
- Dementia
- Diabetes
- Drugs
- Estrogen
- Hypertension
- Hypnotics
- Insulin
- Medicine
- Menopause
- Obesity
- Prescription database
- Sedatives

Fact sheets

Below are links to relevant fact sheets, articles and reports. These may describe trends over time in the Norwegian population or differences by sex, age group, geographical region or socioeconomic status:

- [Topic: Drug consumption](#)
- [Topic: Pain](#)
- [Facts on hypertension \(in Norwegian only\)](#)
- [Chronic Obstructive Pulmonary Disease \(COPD\) in Norway - Public Health Report](#)